Together, these results suggest that there is a clinical opportunity to target the STAT6 pathway in macrophages in HCC and that both patients with CD8-enriched and CD8-poor tumors could benefit from treatment with exoASO-STAT6. Here, STAT6 is linked to hepatocellular carcinoma.